FDA Approves Bimekizumab (Bimzelx) for Psoriatic Arthritis: ACR50 Response 44% in BE COMPLETE Trial

What Is Bimekizumab and How Does It Differ From Other IL-17 Inhibitors?

Bimekizumab is a humanized IgG1 monoclonal antibody developed by UCB that selectively binds and neutralizes both interleukin-17A (IL-17A) and interleukin-17F (IL-17F). While existing IL-17 inhibitors approved for psoriatic arthritis — secukinumab (Cosentyx) and ixekizumab (Taltz) — target only IL-17A, bimekizumab addresses the biological redundancy within the IL-17 family. IL-17F shares approximately 50% structural homology with IL-17A and activates many of the same downstream pro-inflammatory pathways through the IL-17RA/IL-17RC receptor complex, including NF-κB-mediated production of TNF-alpha, IL-6, and matrix metalloproteinases in synovial fibroblasts and chondrocytes.

Preclinical studies have demonstrated that IL-17F contributes independently to joint inflammation, entheseal pathology, and bone erosion in spondyloarthritis models. In synovial tissue from PsA patients, both IL-17A and IL-17F are upregulated, and dual neutralization achieves greater suppression of inflammatory gene expression than IL-17A blockade alone. This more complete pathway inhibition is reflected in the clinical responses observed in the BE COMPLETE trial, particularly in difficult-to-treat manifestations such as enthesitis (inflammation at tendon insertion points) and dactylitis (sausage digits), where residual IL-17F signaling may limit the efficacy of IL-17A-only inhibitors.

How Effective Was Bimekizumab in the BE COMPLETE Trial?

The BE COMPLETE trial was a randomized, double-blind, placebo-controlled Phase 3 study enrolling over 400 adults with active psoriatic arthritis who had an inadequate response or intolerance to at least one TNF inhibitor. Patients were randomized to bimekizumab 160mg subcutaneously every 4 weeks or placebo. Key endpoints included ACR20 and ACR50 response at week 16, PASI90 (90% skin clearance), minimal disease activity (MDA), and resolution of enthesitis and dactylitis.

At week 16, the ACR20 response rate was approximately 66% for bimekizumab versus approximately 27% for placebo (p<0.001). The ACR50 response — a more stringent measure requiring 50% improvement in both tender and swollen joint counts plus three of five additional criteria — was approximately 44% versus about 7% (p<0.001). Among patients with baseline psoriatic skin involvement, approximately 60% on bimekizumab achieved PASI90 versus a substantially lower rate on placebo. Significant improvements in enthesitis resolution and dactylitis resolution were also observed, with bimekizumab demonstrating superiority over placebo across both measures.

Open-label extension data showed sustained responses at one year, with a majority of bimekizumab-treated patients maintaining ACR50 and a substantial proportion achieving minimal disease activity (MDA), a composite endpoint reflecting low disease activity across joints, skin, entheses, and patient-reported outcomes. These sustained responses in a biologic-experienced population represent a clinically meaningful advance, as TNF-inadequate responders typically show attenuated responses to subsequent biologics.

What Are the Side Effects and Safety Profile of Bimekizumab?

The safety profile of bimekizumab in BE COMPLETE was consistent with the established IL-17 inhibitor class and prior bimekizumab data in psoriasis. The most frequently reported adverse events were nasopharyngitis and upper respiratory tract infections, oral candidiasis (approximately 7% versus less than 1% on placebo), and injection-site reactions. The elevated rate of oral candidiasis is a recognized consequence of IL-17 pathway inhibition, as IL-17 signaling plays a critical role in mucosal antifungal immunity. The majority of candidiasis cases were mild to moderate, responsive to topical antifungal therapy, and did not require treatment discontinuation.

Serious adverse events occurred at low and comparable rates across treatment groups. No cases of inflammatory bowel disease (a theoretical concern with IL-17 inhibition) were attributed to the drug in the controlled period. Serious infections were uncommon, with no opportunistic infections other than candidiasis reported. The prescribing information recommends screening for latent tuberculosis prior to initiation and monitoring for signs of oral candidiasis, with consideration of prophylactic antifungal therapy in patients with recurrent candidiasis history. Overall, the safety profile is consistent with the broader IL-17 inhibitor class, with the higher candidiasis rate being the principal distinguishing adverse event attributable to additional IL-17F blockade.

How Does Bimekizumab Compare to Secukinumab and Ixekizumab?

While no head-to-head trials have directly compared bimekizumab to secukinumab or ixekizumab specifically in psoriatic arthritis, cross-trial comparisons and the head-to-head BE RADIANT study in plaque psoriasis provide informative context. In BE RADIANT, published in the New England Journal of Medicine in 2021, bimekizumab demonstrated superior skin clearance rates compared to secukinumab 300mg at week 16, establishing a clear advantage for the skin manifestation. In PsA, the ACR50 rates for secukinumab in the FUTURE series of trials (approximately 29–34% in biologic-naive patients) and ixekizumab in SPIRIT-P2 (approximately 31% in TNFi-experienced patients) provide a benchmark against bimekizumab's approximately 44% in a biologic-experienced population — a notably more difficult-to-treat cohort.

From a practical standpoint, bimekizumab offers every-4-week dosing after the initial period, compared to secukinumab's weekly loading doses followed by every-4-week maintenance and ixekizumab's every-2-week initial dosing transitioning to every-4-week. The principal safety trade-off is the higher rate of oral candidiasis with bimekizumab (~7%) compared to secukinumab (~1–2%) and ixekizumab (~2–3%), attributable to the additional IL-17F inhibition reducing mucosal antifungal defenses. Cost will be a key determinant of adoption, with bimekizumab expected to be priced comparably to existing IL-17 inhibitors. Treatment guidelines from the American College of Rheumatology and Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) are expected to incorporate bimekizumab into updated PsA management algorithms.